Overall, our observations contribute to the validation of the RyR2 channel as an intracellular therapeutic target for treating CPVT patients, thereby refocusing our attention on the molecular basis of the CPVT disorder. Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.